Figure 3
Figure 3. Anti–IL-21 mAb treatment decreases CD8+ T-cell numbers in xenogeneic GVHD and increases the percentage of CD4+ cells expressing Foxp3. NOD/SCID/γc−/− mice receiving human HLA-A2− PBMCs (30 × 106 cells) were treated with anti–IL-21 mAb, isotype control antibody, or in vitro expanded, HLA-A2+ nTregs and were electively killed on days 10 and 20. Average number (± SEM) of human CD4+HLA-A2− (A), CD8+HLA-A2− (B) T cells in spleen or microliter of blood, or ratio of CD4/CD8 (gated for HLA-A2−) on day 20 (C). Relative (D) or total (E) number (× 104; ± SEM) of human CD4+HLA-A2−Foxp3+ cells in spleen on day 10 or day 20. n = 3 or 4 mice for each time point (day 10 and day 20) and each treatment group, and data shown are representative of 2 independent experiments.

Anti–IL-21 mAb treatment decreases CD8+ T-cell numbers in xenogeneic GVHD and increases the percentage of CD4+ cells expressing Foxp3. NOD/SCID/γc−/− mice receiving human HLA-A2 PBMCs (30 × 106 cells) were treated with anti–IL-21 mAb, isotype control antibody, or in vitro expanded, HLA-A2+ nTregs and were electively killed on days 10 and 20. Average number (± SEM) of human CD4+HLA-A2 (A), CD8+HLA-A2 (B) T cells in spleen or microliter of blood, or ratio of CD4/CD8 (gated for HLA-A2) on day 20 (C). Relative (D) or total (E) number (× 104; ± SEM) of human CD4+HLA-A2Foxp3+ cells in spleen on day 10 or day 20. n = 3 or 4 mice for each time point (day 10 and day 20) and each treatment group, and data shown are representative of 2 independent experiments.

Close Modal

or Create an Account

Close Modal
Close Modal